Medtronic grows patient monitoring offerings with BioIntelliSense partnership

Wearable patient monitors can help with healthcare staffing shortages, an ongoing challenge for hospitals, and create an opportunity for device makers.

By Ricky Zipp • Sept. 1, 2022

Akili CEO Martucci sees ‘massive’ need for company’s ADHD video-game treatment

With enough cash now to last two years, the company hopes it can change the way children with ADHD are treated, offering an alternative to pharmaceuticals.

By Elise Reuter • Aug. 29, 2022

Explore the Trendline➔

Medical device industry continues to turn to AI

While the industry continues to embrace artificial intelligence, there are still questions about how the new technologies need to be regulated and if they are effective.

By MedTech Dive staff

The future of healthcare technology is remote patient monitoring — here’s what you need to know

Organizations leading the charge in remote monitoring innovation are setting themselves up for long-term success.

Aug. 29, 2022

Review finds ‘paucity of robust evidence’ on impact of AI clinical outcomes

Of the nearly 12,000 articles on artificial intelligence, only 39 described randomized controlled trials, making it difficult to quantify the clinical benefits of using AI-assisted tools for patient care.

By Nick Paul Taylor • Aug. 26, 2022

Insulet’s Omnipod 5 insulin delivery system approved for preschool children

Adding preschoolers will broaden the market for the Omnipod after the launch of the device for people aged six years and older helped Insulet boost U.S. sales by 31% in the second quarter.

By Nick Paul Taylor • Aug. 23, 2022

Akili raises $163M in ‘blank-check’ merger, plans to commercialize digital treatment for ADHD

Akili’s share price fell as much as 55 percent on the Nasdaq by mid-morning Monday, its first day of trading after merging with a special purpose acquisition company.

By Elise Reuter • Aug. 22, 2022

Visibly wins FDA clearance for self-administered online vision test

The agency has placed restrictions on the test, limiting it to adults aged 22 to 40 years and cautioning that it only gives “supportive recommendations.”

By Nick Paul Taylor • Aug. 17, 2022

Smartphone-linked blood pressure monitors fail to beat traditional devices, study finds

Individuals have been able to check their blood pressure at home using devices that lack connectivity features for years, raising the question of whether the technology improves outcomes.

By Nick Paul Taylor • Aug. 16, 2022

Pear Therapeutics trims workforce, forecast as state contracts move slower than expected

After a restructuring in July, the company is focused on bringing in more paying customers.

By Elise Reuter • Aug. 12, 2022

Friday Q&A: Francine Kaufman, Senseonics’ CMO, talks growing users, a 365-day CGM, doctor recruitment

Kaufman spoke about Senseonics’ release of its 180-day CGM in the U.S., developing a unique product in the diabetes technology market and competing with Dexcom and Abbott.

By Ricky Zipp • Aug. 12, 2022

Insulet raises forecast as Omnipod 5 sales climb; Tandem expects tougher market in second half

Both insulin pump companies grew revenue by more than 10% in the second quarter, but Tandem lowered its 2022 forecast amid a tougher market, while Insulet increased its guidance.

By Ricky Zipp • Aug. 11, 2022

Roundup: Medical device industry confident it can ride out recession, wary of slowing capital sales

While companies may weather a recession, they still face challenges like hospital staffing shortages, supply chain disruption and inflation, RBC Capital Markets analysts wrote.

By Nick Paul Taylor • Updated Aug. 10, 2022

Senate passes $740B bill to lower healthcare costs after months of wrangling

While Republicans successfully challenged a planned $35 insulin price ceiling for patients on private insurance, the law still has implications for makers of diabetes devices.

By Nick Paul Taylor • Aug. 8, 2022

FDA’s breakthrough device designations poised for another record year

At the midpoint of the year, the FDA had granted 129 designations, suggesting it will break the previous full-year record of 206.

By Nick Paul Taylor • Aug. 8, 2022

iRhythm raises 2022 revenue forecast after record number of registrations in Q2

The cardiac monitor maker increased the low end of its forecast by $5 million, although executives expect a flat third quarter compared to the second quarter due to macroeconomic pressures.

By Ricky Zipp • Aug. 5, 2022

ResMed buys Mementor for prescription digital health app, continuing German expansion

ResMed will integrate the startup into its German operation as a separate business segment and use it as a platform for further digital health development.

By Nick Paul Taylor • Aug. 4, 2022

Dexcom’s G7 glucose monitor delayed until late 2022; stock price drops 5.6%

The CGM maker needs to update software for the product, pushing back the FDA’s decision and eventual U.S. release.

By Ricky Zipp • July 29, 2022

Pear Therapeutics restructures, looks to slash development costs

The digital therapeutics company is looking to cut down on the development of new product candidates to focus on near-term commercialization plans.

By Elise Reuter • Updated July 28, 2022

iRhythm, Alphabet unit Verily get FDA clearances for Zio Watch and software system

Bolstered by an AI algorithm, the companies’ partnership is a step closer to catching up with the Apple Watch.

By Ricky Zipp • July 25, 2022

Turning your unique brand knowledge into stronger HCP relationships

How life science companies can translate their extensive brand knowledge into a digital, forward-looking HCP engagement strategy.

July 25, 2022

Johns Hopkins sepsis alert tool reduced patient deaths, studies find

Three prospective studies of a machine learning tool developed by a Johns Hopkins spinout found it led to earlier antibiotic treatment and reduced patient mortality.

By Elise Reuter • July 22, 2022

FDA patient advisers grapple with consent, oversight of virtual-reality devices in healthcare

The advisory group addressed patient consent in surgeries using augmented reality tools and how to distinguish clinical uses of virtual reality from entertainment products. 

By Elise Reuter • July 20, 2022

iRhythm says Q2 unit volumes beat forecast, names Chad Patterson as new CCO

The company noted the results are preliminary and may change before its Aug. 4 earnings call.

By Ricky Zipp • July 19, 2022

Lack of payment pathway clarity hinders digital therapeutics, analysts say

The report warns of a sector beset by payment issues, “snake oil” and “middling adoption.”

By Nick Paul Taylor • July 15, 2022

CMS proposes national rates for cardiac monitoring; iRhythm's stock jumps

The proposed rule could end a years-long saga for the cardiac market, although pricing specifics may change in the final version.

By Ricky Zipp • July 8, 2022